Sugi Predict

Sugi Predict / Compounds / SCHEMBL473969

SCHEMBL473969

SCHEMBL473969

CC(=O)c1ccc(F)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.53
▸ NPC1 O15118 3/20 0.48
▸ P2RX7 Q99572 2/20 0.48
▸ CES2 O00748 1/20 0.47
▸ CES1 P23141 1/20 0.47
▸ RAB9A P51151 2/20 0.45
▸ PYGL P06737 4/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ ALOX15 P16050 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ HSD11B1 P28845 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30231714 1.00 HPGD (0.53) HPGDNPC1P2RX7CES2CES1
SCHEMBL5884181 0.83 CES2 (0.47) HPGDCES2CES1ALDH1A1LMNA
SCHEMBL23755037 0.83 CES2 (0.61) HPGDNPC1P2RX7CES2CES1
SCHEMBL2861947 0.83 HPGD (0.61) HPGDNPC1P2RX7CES2CES1
SCHEMBL29873483 0.83 CES2 (0.61) HPGDNPC1P2RX7CES2CES1
SCHEMBL6071851 0.83 HPGD (0.47) HPGDNPC1P2RX7CES2CES1
SCHEMBL106341 0.81 HPGD (0.54) HPGDNPC1P2RX7CES2CES1
SCHEMBL195310 0.81 TSHR (0.63) HPGDNPC1P2RX7CES2CES1
SCHEMBL4867735 0.80 HPGD (0.50) HPGDNPC1P2RX7RAB9APYGL
SCHEMBL15094211 0.80 HPGD (0.46) HPGDNPC1P2RX7CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116444360-B Synthesis method of saflufenacil intermediate 2-chloro-4-fluorobenzoic acid 浙江工业大学 2026-03-24 — — CN disclosed
EP-4703361-A1 PYRIDAZINONE TRPC4/5 INHIBITOR AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2026-03-04 — — EP disclosed
US-12281079-B2 Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2025-04-22 — — US disclosed
US-20240391875-A1 ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2024-11-28 — — US disclosed
US-20240368106-A1 HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2024-11-07 — — US disclosed
WO-2024222379-A1 PYRIDAZINONE TRPC4/5 INHIBITOR AND USE THEREOF 中国科学院上海药物研究所 2024-10-31 — — WO disclosed
CN-118834210-A Pyridazinone TRPC4/5 inhibitor and application thereof 中国科学院上海药物研究所 2024-10-25 — — CN disclosed
CN-118684657-A 1, 2-Benzopyrone derivative, preparation method and medical application thereof 中国药科大学 2024-09-24 — — CN disclosed
CN-115043779-B 2, 4-Diphenyl imidazole compound and preparation method and application thereof 广东金柏化学有限公司 2024-06-25 — — CN disclosed
CN-115088722-B Application, method and composition of diphenyl ether compound containing triazole structure in preventing and controlling plant diseases 海利尔药业集团股份有限公司 2024-06-21 — — CN disclosed
WO-1989004827-A1 PROCESS FOR THE SYNTHESIS OF 3-THIO-4-QUINOLONE DERIVATIVES AND INTERMEDIATE COMPOUNDS FOR USE THEREIN, AND THEIR USE AS MEDICAMENTS THE BOOTS COMPANY PLC (GB) 1989-06-01 — — WO disclosed
EP-0317997-A2 1,4-Disubstituted-piperidinyl compounds MERRELL DOW PHARMACEUTICALS INC. (US) 1989-05-31 — — EP disclosed
EP-0317149-A1 Process for the synthesis of 3-thio-4-quinolone derivatives and intermediate compounds for use therein, and their use as medicaments The Boots Company PLC (GB) 1989-05-24 — — EP disclosed
EP-0306300-A2 Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1989-03-08 — — EP disclosed
US-4751310-A Inhibition of the 5-lipoxygenase pathway SMITHKLINE BECKMAN CORPORATION (US) 1988-06-14 — — US disclosed
US-4719218-A ENZYME INHIBITORS SMITHKLINE BECKMAN CORPORATION (US) 1988-01-12 — — US disclosed
EP-0231622-A2 Inhibition of the 5-lipoxygenase pathway SMITHKLINE BEECHAM CORPORATION (US) 1987-08-12 — — EP disclosed
EP-0207894-A1 Herbicidally active derivatives of N-phenyl-3,4,5,6-tetrahydrophthalimide CIBA-GEIGY AG (CH) 1987-01-07 — — EP disclosed
US-4017631-A MICROBIOCIDES JANSSEN PHARMACEUTICA N.V. (BE) 1977-04-12 — — US disclosed
US-3991202-A ANTIMICROBIALS JANSSEN PHARMACEUTICA N.V. (BE) 1976-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240391875-A1 ISOQUINOLINONES AND QUINOLINONES AS MODULATORS OF POLRMT POLRMT, TFAM, POLM HPGD 1674/4885NPC1 1431/4885P2RX7 3732/4885
US-12281079-B2 Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer AVPR2, AVPR1A, VHL HPGD 570/4885NPC1 1788/4885P2RX7 1272/4885
US-20240368106-A1 HYDROXY AND ALKOXY COUMARINS AS MODULATORS OF POLRMT POLRMT, ACAT1, TFAM HPGD 882/4885NPC1 700/4885P2RX7 3675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.